TLR9 and systemic lupus erythematosus: These effects of T cells may rely on cytokine production by the T cells, in keeping with previous findings that in-vitro activated T cells from healthy donors and SLE patients enhance the secretion of IFN-α from pDCs stimulated with the TLR9-agonist ODN2216 (22).